Nisha Pandey

Health and Me

New Lymphoma Trial: Experimental Drug Combination Cuts Progression Or Death Risk By 51%

A new drug combination has shown promise in treating people diagnosed with diffuse large B-cell <span>lymphoma</span> (<span>DLBCL</span>), reducing the risk of progression or death by 51% compared to the current treatment alone. 

The findings come from the Phase 3 EPCORE DLBCL-2 trial, which tested the addition of <span>epcoritamab</span> to R-CHOP, a standard chemotherapy and immunotherapy regimen used to treat DLBCL. The companies developing the drug, <span>Genmab</span> and AbbVie, announced the ]results on October 5. 

<h2>Findings From The Lymphoma Trial </h2>

The trial evaluated newly diagnosed patients with DLBCL and other <a href="https://www.healthandme.com/health-news/fda-approves-targeted-cancer-drug-as-first-line-treatment-for-cll-that-cuts-progression-risk-by-80-article-156270532" data-type="tilCustomLink">large B-cell lymphomas</a> who had an International Prognostic Index (IPI) score of 2 to 5, indicating varying levels of disease risk. 

Patients received either epcoritamab plus R-CHOP or R-CHOP alone. The combination reduced the risk of disease progression or death by 51%, with a hazard ratio of 0.49 and a p-value below 0.0001. The benefit was seen in the trial’s primary higher-risk group as well as the broader population included in the study. 

The companies said this is the first Phase 3 study of a bispecific antibody combination to demonstrate a significant improvement in progression-free survival in newly diagnosed DLBCL.

Also read: <a href="https://www.healthandme.com/parenting/world-meningitis-day-why-1-in-3-meningitis-deaths-occur-in-children-under-5-article-156278649" data-type="tilCustomLink">World Meningitis Day: Why 1 In 3 Meningitis Deaths Occur In Children Under 5</a> 

Epcoritamab is a bispecific antibody that engages T-cell. Unlike chemotherapy, which directly targets rapidly dividing cells, the drug is designed to bring the body’s immune cells into closer contact with cancer cells. 

It binds to CD3 on T cells and CD20 on B cells, effectively directing T cells towards CD20-positive <a href="https://www.healthandme.com/health-news/could-a-longer-endoscopy-help-spot-more-gastric-cancers-wcog-2026-highlights-significance-of-early-detection-article-156272790" data-type="tilCustomLink">cancer</a> cells so they can attack them. 

R-CHOP, meanwhile, combines rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone and has been a standard treatment for DLBCL for decades. 

“DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a new standard of care in newly diagnosed DLBCL patients,” said Daejin Abidoye, MD, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology, AbbVie.

Also read: <a href="https://www.healthandme.com/health-news/congo-ebola-outbreak-obeldesivir-trial-advances-with-250-participants-as-death-toll-crosses-4000-article-156276436" data-type="tilCustomLink">Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000</a>

<h2>Hope For A New Course Of Treatment In Blood Cancer </h2>

Fatty Liver Explained: Causes, Symptoms, Treatment, Reversal & Who Is at Risk

DLBCL is the most common type of <a href="https://www.healthandme.com/health-wellness/amanda-peets-breast-cancer-wasnt-a-lump-what-was-her-first-sign-article-156260232" data-type="tilCustomLink">non-Hodgkin lymphoma</a>, accounting for around 25% to 30% of non-Hodgkin lymphoma cases worldwide. Although R-CHOP has improved outcomes, some patients still experience disease progression or relapse. 

The new findings suggest that bringing a bispecific antibody into treatment from the time of initial diagnosis could improve how long patients remain free from disease progression. 

“As an investigator with firsthand experience in both the landmark trial that established R-CHOP as a standard of care nearly 25 years ago and EPCORE DLBCL-2, it is particularly meaningful to see the potential benefit of bispecific antibody therapy in newly diagnosed diffuse large B-cell lymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center. 

But the combination is still investigational and has not been approved for newly diagnosed DLBCL. The companies said they plan to engage regulatory authorities globally based on the results. 

Full trial data will also be presented at a future medical meeting, meaning detailed results, including the complete safety and survival data, are still awaited.

Health Conditions A-Z

health

new-lymphoma-trial-experimental-drug-combination-cuts-progression-or-death-risk-by-51

Lymphoma

r chop

diffuse large B cell lymphoma

epcoritamab

dlbcl

lymphomas

genmab

starbucks-gets-sued-over-sugar-free-protein-drinks-containing-up-to-21-grams-of-sugar-health-risks-explained

Starbucks Gets Sued Over ‘Sugar-Free’ Protein Drinks Containing Up To 21 Grams Of Sugar: Health Risks Explained

pneumonic-plague-us-eu-monitor-suspected-case-in-russia-call-for-more-surveillance

Pneumonic Plague: US, EU Monitor Suspected Case in Russia, Call for More Surveillance

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A new drug combination has shown promise in treating people diagnosed with diffuse large B-cell lymphoma (DLBCL), reducing the risk of progression or death by 51% compared to the current treatment alone. The findings come from the Phase 3 EPCORE DLBCL-2 trial, which tested the addition of epcoritamab to R-CHOP, a standard chemotherapy and immunotherapy regimen used to treat DLBCL. The companies developing the drug, Genmab and AbbVie, announced the ]results on October 5. Findings From The Lymphoma Trial The trial evaluated newly diagnosed patients with DLBCL and other large B-cell lymphomas who had an International Prognostic Index (IPI) score of 2 to 5, indicating varying levels of disease risk. Patients received either epcoritamab plus R-CHOP or R-CHOP alone. The combination reduced the risk of disease progression or death by 51%, with a hazard ratio of 0.49 and a p-value below 0.0001. The benefit was seen in the trial’s primary higher-risk group as well as the broader population included in the study. The companies said this is the first Phase 3 study of a bispecific antibody combination to demonstrate a significant improvement in progression-free survival in newly diagnosed DLBCL.Also read: World Meningitis Day: Why 1 In 3 Meningitis Deaths Occur In Children Under 5 How Does Epcoritamab Work? Epcoritamab is a bispecific antibody that engages T-cell. Unlike chemotherapy, which directly targets rapidly dividing cells, the drug is designed to bring the body’s immune cells into closer contact with cancer cells. It binds to CD3 on T cells and CD20 on B cells, effectively directing T cells towards CD20-positive cancer cells so they can attack them. R-CHOP, meanwhile, combines rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone and has been a standard treatment for DLBCL for decades. “DLBCL is an aggressive disease and the need to advance treatment options is critical. These positive topline results suggest that epcoritamab combined with R-CHOP could offer a new standard of care in newly diagnosed DLBCL patients,” said Daejin Abidoye, MD, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology, AbbVie.Also read: Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000Hope For A New Course Of Treatment In Blood Cancer    DLBCL is the most common type of non-Hodgkin lymphoma, accounting for around 25% to 30% of non-Hodgkin lymphoma cases worldwide. Although R-CHOP has improved outcomes, some patients still experience disease progression or relapse. The new findings suggest that bringing a bispecific antibody into treatment from the time of initial diagnosis could improve how long patients remain free from disease progression. “As an investigator with firsthand experience in both the landmark trial that established R-CHOP as a standard of care nearly 25 years ago and EPCORE DLBCL-2, it is particularly meaningful to see the potential benefit of bispecific antibody therapy in newly diagnosed diffuse large B-cell lymphoma,” said Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center. But the combination is still investigational and has not been approved for newly diagnosed DLBCL. The companies said they plan to engage regulatory authorities globally based on the results. Full trial data will also be presented at a future medical meeting, meaning detailed results, including the complete safety and survival data, are still awaited.

new lymphoma trial: experimental drug combination cuts progression or death risk by 51%

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

New Lymphoma Trial: Experimental Drug Combination Cuts Progression Or Death Risk By 51%

Pneumonic Plague: US, EU Monitor Suspected Case in Russia, Call for More Surveillance

Over 2 Hours of Daily Screen Time Linked to Depression, Obesity In Young People: Lancet

Russia Plague Scare: Could It Trigger A New Pandemic? Experts Explain

Health Conditions A-Z

Starbucks Gets Sued Over ‘Sugar-Free’ Protein Drinks Containing Up To 21 Grams Of Sugar: Health Risks Explained

New Lymphoma Trial: Experimental Drug Combination Cuts Progression Or Death Risk By 51%

Pneumonic Plague: US, EU Monitor Suspected Case in Russia, Call for More Surveillance